Nurix Therapeutics Inc [NASDAQ: NRIX] loss -0.59% or -0.13 points to close at $21.86 with a heavy trading volume of 4092456 shares.
The daily chart for NRIX points out that the company has recorded 27.02% gains over the past six months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If we look at the average trading volume of 642.66K shares, NRIX reached to a volume of 4092456 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Nurix Therapeutics Inc [NRIX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NRIX shares is $29.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NRIX stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Nurix Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on September 06, 2024. While these analysts kept the previous recommendation, Truist raised their target price to Buy. The new note on the price target was released on July 31, 2024, representing the official price target for Nurix Therapeutics Inc stock. Previously, the target price had yet another raise to $25, while Oppenheimer analysts kept a Outperform rating on NRIX stock.
The Average True Range (ATR) for Nurix Therapeutics Inc is set at 1.21, with the Price to Sales ratio for NRIX stock in the period of the last 12 months amounting to 22.60. The Price to Book ratio for the last quarter was 3.80, with the Price to Cash per share for the same quarter was set at 6.88.
Trading performance analysis for NRIX stock
Nurix Therapeutics Inc [NRIX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.88. With this latest performance, NRIX shares dropped by -8.04% in over the last four-week period, additionally plugging by 27.02% over the last 6 months – not to mention a rise of 225.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NRIX stock in for the last two-week period is set at 40.71, with the RSI for the last a single of trading hit 37.05, and the three-weeks RSI is set at 44.40 for Nurix Therapeutics Inc [NRIX]. The present Moving Average for the last 50 days of trading for this stock 23.14, while it was recorded at 21.92 for the last single week of trading, and 16.51 for the last 200 days.
Nurix Therapeutics Inc [NRIX]: A deeper dive into fundamental analysis
Nurix Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.57 and a Current Ratio set at 5.57.
An analysis of Institutional ownership at Nurix Therapeutics Inc [NRIX]
There are presently around $104.20%, or 105.88%% of NRIX stock, in the hands of institutional investors. The top three institutional holders of NRIX stocks are: BLACKROCK INC. with ownership of 6.82 million shares, which is approximately 12.4218%. REDMILE GROUP, LLC, holding 4.42 million shares of the stock with an approximate value of $$92.32 million in NRIX stocks shares; and REDMILE GROUP, LLC, currently with $$83.3 million in NRIX stock with ownership which is approximately 7.27%.
